Uterine Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The uterine cancer therapeutics & diagnostics market is segmented by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), Product, and Geography

Market Snapshot

Uterine Cancer Therapeutics & Diagnostics Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6 %
Uterine Cancer Therapeutics & Diagnostics Market Major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Uterine Cancer Therapeutics & Diagnostics Market is expected to witness a growth of 6% CAGR owing to the growing awareness of uterine cancer and increasing healthcare expenditure. In the United States, the month of September is Gynecologic Cancer Awareness Month. The American Association for Cancer Research has stated in its article that endometrial carcinoma is common across the globe whereas, Uterine Sarcoma is considered as a rare type of cancer. CDC has stated that around 68% of the uterine cancers are the endometrial carcinomas.

Furthermore, developing countries like India has a National Cancer Control Programme which was established in 1975–76. This has contributed to the development of Regional Cancer Centres (RCCs), oncology wings in medical colleges and support for the purchase of teletherapy machines. In this country, the awareness programmes about the cancer are being conducted which is making the women aware of the severity of the disease.

Looking at the severity of the disease and importance of the women health, healthcare providers along with the governments are provoking awareness programmes in certain regions such as North America, Europe, and Asia-Pacific. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly in the over the forecast period.

Scope of the Report

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Radiation Therapy
Pelvic Ultrasound
Dilation and Curettage
CT Scan
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Endometrial Adenocarcinoma to Witness Highest Growth Over the Forecast Period

Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment. According to the Cancer.gov, an endometrial adenosarcoma is the most common type of cancer which is found in women and about 80 percent of uterine cancers are adenocarcinomas, and vary in degree of severity.

Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma as around 90% of the uterine cancers affect the endometrium. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.

Uterine Cancer Therapeutics & Diagnostics Market  Trends

North America is Expected to Dominate the Market over the Forecast Period

North America region is believed to dominate the Global Uterine Cancer Therapeutics and Diagnostics Market in the near future. The prime reason for the growth of the market in this region is the rising incidence of the disease and the growing awareness among the general population. American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, around 10% of uterine body cancers are sarcoma. In addition, rapid technological advancements in the diagnostics and faster adoption to new technologies in the country are provoking the overall growth of the market studied.

Uterine Cancer Therapeutics & Diagnostics Market Share

Competitive Landscape

The market studied is moderately competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. Surgery

        2. Immunotherapy

        3. Radiation Therapy

        4. Chemotherapy

        5. Others

      2. 5.2.2 Diagnostics

        1. Biopsy

        2. Pelvic Ultrasound

        3. Hysteroscopy

        4. Dilation and Curettage

        5. CT Scan

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Ariad Pharmaceuticals, Inc.

      2. 6.1.2 Abbott Laboratories

      3. 6.1.3 Becton, Dickinson & Co.

      4. 6.1.4 GlaxoSmithKline Plc

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Novartis AG

      7. 6.1.7 Sanofi

      8. 6.1.8 Siemens Healthcare Inc.

      9. 6.1.9 Roche Ltd

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Uterine Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Uterine Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, Becton Dickinson and Company, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc. are the major companies operating in Uterine Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!